SERATICIN® Antibacterial Technology Based on Maggot Secretions
Chemical, Healthcare and Pharmaceuticals, Life Sciences
About The Opportunity:
Maggot secretions have been used for centuries to treat and clean wounds. At Swansea University a technology, trademarked under the name SERATICIN®, has been developed to treat various bacterial infections, including MRSA, using a synthetic, small-molecule version of an extract from maggot secretions. SERATICIN® offers the prospect of a highly effectively antibacterial candidate in a format compatible with modern drug delivery modes with minimal drug resistance and side-effects.
- The antibacterial technology is being developed for use in a topical format although it is hoped to advance an oral medication with further investment. It is expected to be used in both the animal and human antibiotic markets.
- Early experiments indicate a strong and broad antibacterial potential;
- Minimal drug resistance to a novel, first in class bactericidal agent;
- Potential for a range of drug delivery mechanisms.
A patent has been granted under application no. PCT/GB2008/000157 and a second patent on the chemical structure is pending under application no. PCT/GB2012/053138.
The invention is offered for exclusive or non-exclusive licence.
See more at: